Loading
A phase 2/3 trial testing MK-1045 in acute lymphoblastic leukaemia, now recruiting.
A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukaemia (MK-1045-005) is a phase 2/3 interventional study registered as NCT07570173, led by Merck Sharp & Dohme, and recruiting on the registry. Official title: A Phase 2/3, Randomised, Open-Label, Comparison Study of MK-1045 Versus Blinatumomab in Participants With Relapsed or Refractory CD19+ B-Cell Acute Lymphoblastic Leukaemia (B-ALL). Planned enrolment is 340 participants (estimated). The study started in 2026-05-18 and primary completion is expected in 2033-10-18. No results have been posted on ClinicalTrials.gov.
Shares MK-1045, Merck & Co. (MSD), Acute lymphoblastic leukaemia.
Shares MK-1045, Merck & Co. (MSD).
Shares MK-1045, Merck & Co. (MSD).